Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition

被引:112
作者
van de Wal, RMA
Plokker, HWM
Lok, DJA
Boomsma, F
van der Horst, FAL
van Veldhuisen, DJ
van Gilst, WH
Voors, AA
机构
[1] St Antonius Hosp, Dept Cardiol, NL-3435 CM Nieuwegein, Netherlands
[2] Deventer Hosp, Dept Cardiol, NL-7515 CM Deventer, Netherlands
[3] Erasmus Univ, Med Ctr, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands
[4] St Antonius Hosp, Dept Clin Chem, NL-3435 CM Nieuwegein, Netherlands
[5] Univ Groningen Hosp, Dept Cardiol, NL-9700 RB Groningen, Netherlands
[6] Univ Groningen, Dept Clin Pharmacol, NL-9713 AV Groningen, Netherlands
关键词
angiotensin II; chronic heart failure; ACE inhibition;
D O I
10.1016/j.ijcard.2005.02.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The beneficial effects of ACE inhibitors are generally ascribed to blockade of neurohormonal activation. However, especially in chronic heart failure (CHF) patients plasina angiotensin II and aldosterone levels can be elevated despite ACE inhibition, the so-called ACE escape. In the present study, we aimed to identify the frequency and determinants of ACE escape in CHF patients. Methods: We studied 99 stable chronic heart failure patients (NYHA class III and IV, 66% ischemic etiology) receiving long-term therapy with ACE inhibitors. In all patients, cardiac, renal, and neurohormonal parameters were measured. ACE escape was defined as plasma angiotensin level >= 16 pmol/L. Results: Mean (SD) left ventricular ejection fraction of our 99 patients (79 men and 20 women,. age 69 +/- 12 years) was 28 +/- 10%. In addition to an ACE inhibitor, 93% of patients received diuretics, 71% a beta-blocker, and 49% spironolactone. None of the patients used an angiotensin receptor blocker. In our population, 45% of the patients had an angiotensin II plasma concentration higher than 16 pmol/L (median concentration was 14.1 pmol/L). Spironolactone use was an independent predictor of elevated plasma angiotensin II levels. Furthermore, spironolactone users had significantly higher plasma active renin protein and aldosterone levels. Plasma angiotensin It concentration was positively correlated to active renin, plasma angiotensin I and plasma aldosterone. No correlation was found between plasma angiotensin II levels and serum ACE activity, dose of ACE inhibitor, or duration of use. Conclusion: In a group of severe chronic heart failure patients, 45% had elevated plasma angiotensin II levels independent of serum ACE activity despite long-term ACE inhibitor use. Although a causal link could not be proven, an association was found between spironolactone use and active renin protein, angiotensin II and aldosterone levels, suggesting that escape from ACE is mainly caused by a feedback mechanism. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:367 / 372
页数:6
相关论文
共 29 条
[1]   METABOLISM AND PRODUCTION OF ANGIOTENSIN-I IN DIFFERENT VASCULAR BEDS IN SUBJECTS WITH HYPERTENSION [J].
ADMIRAAL, PJJ ;
DERKX, FHM ;
DANSER, AHJ ;
PIETERMAN, H ;
SCHALEKAMP, MADH .
HYPERTENSION, 1990, 15 (01) :44-55
[2]   EFFECT OF LONG-TERM ENALAPRIL THERAPY ON NEUROHORMONES IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION [J].
BENEDICT, CR ;
FRANCIS, GS ;
SHELTON, B ;
JOHNSTONE, DE ;
KUBO, SH ;
KIRLIN, P ;
NICKLAS, J ;
LIANG, CS ;
KONSTAM, MA ;
GREENBERG, B ;
YUSUF, S .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (16) :1151-1157
[3]   ANTIHYPERTENSIVE THERAPY WITH MK-421 - ANGIOTENSIN-II-RENIN RELATIONSHIPS TO EVALUATE EFFICACY OF CONVERTING ENZYME BLOCKADE [J].
BIOLLAZ, J ;
BRUNNER, HR ;
GAVRAS, I ;
WAEBER, B ;
GAVRAS, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 (06) :966-972
[4]   OPPOSITE EFFECTS OF CAPTOPRIL ON ANGIOTENSIN I-CONVERTING ENZYME-ACTIVITY AND CONCENTRATION - RELATION BETWEEN ENZYME-INHIBITION AND LONG-TERM BLOOD-PRESSURE RESPONSE [J].
BOOMSMA, F ;
DEBRUYN, JHB ;
DERKX, FHM ;
SCHALEKAMP, MADH .
CLINICAL SCIENCE, 1981, 60 (05) :491-498
[5]   SINGLE AND REPEATED DOSING OF THE CONVERTING-ENZYME-INHIBITOR PERINDOPRIL TO NORMAL SUBJECTS [J].
BUSSIEN, JP ;
DAMORE, TF ;
PERRET, L ;
PORCHET, M ;
NUSSBERGER, J ;
WAEBER, B ;
BRUNNER, HR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (05) :554-558
[6]   Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype [J].
Cicoira, M ;
Zanolla, L ;
Rossi, A ;
Golia, G ;
Franceschini, L ;
Cabrini, G ;
Bonizzato, A ;
Graziani, M ;
Anker, SD ;
Coats, AJS ;
Zardini, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (07) :1808-1812
[7]   Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure [J].
Davidson, NC ;
Coutie, WJ ;
Webb, DJ ;
Struthers, AD .
HEART, 1996, 75 (06) :576-581
[8]   Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes [J].
Davies, JI ;
Band, M ;
Morris, A ;
Struthers, AD .
DIABETOLOGIA, 2004, 47 (10) :1687-1694
[9]   Pathologic consequences of increased angiotensin II activity [J].
Ferrario, CM ;
Flack, JM .
CARDIOVASCULAR DRUGS AND THERAPY, 1996, 10 (05) :511-518
[10]   EFFECTS OF ANGIOTENSIN CONVERTING ENZYME-INHIBITION, SODIUM DEPLETION, CALCIUM, ISOPROTERENOL, AND ANGIOTENSIN-II ON RENIN SECRETION BY INDIVIDUAL RENOCORTICAL CELLS [J].
GEARY, KM ;
HUNT, MK ;
PEACH, MJ ;
GOMEZ, RA ;
CAREY, RM .
ENDOCRINOLOGY, 1992, 131 (04) :1588-1594